The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 47%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (1 analysts) rates it none, with a mean price target of $60.
Arqit Quantum Inc
ARQQ · NASDAQ · USD · Market cap $303M · 87 employees
Arqit Quantum Inc.
FAIL · Does not pass the screenAt the last full screen
2025-09-30
Screened 2025-09-30 · the tape above runs as of 09:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its distribution label.
Arqit Quantum Inc holds its Distribution at $17.42. Elevated stress, defensive posture warranted, held for 25 days.
| Phase | Distribution · caution |
| Quantitative state | Elevated stress, defensive posture warranted, held for 25 days |
| Price at the screen | $17.42 |
| Valuation | N/A trailing · -16.43 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 2.21 |
Five Screens, Shown in Full
Does not pass. Accounts receivable
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 1.68% | Below 33% | Interest-bearing debt is just 1.7% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 87.83% | Below 49% | Money owed to the company is 87.8% of assets, above the 49% limit. | Fail |
| Revenue purity | 232.45% | Below 5% | 232.5% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Business, in Plain Words| Forward P/E | -16.4x |
| EPS, trailing | -3.03 |
| EPS, forward | -1.06 |
| Revenue growth | +829.9%growing very fast |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -220.2%not currently earning a positive return on equity |
| FCF yield | -6.50% |
| Debt to equity | 0.08minimal debt: a conservative balance sheet |
| Current ratio | 4.88comfortably covers its short-term bills |
| Beta | 2.21much more volatile than the market |
| Short interest, float | 0.25% |
| 52-week range | 11.52 - 62.00 |
| Moat | NONE |
| Market cap | $303M |
| Employees | 87 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeARQQ trades on NASDAQ (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 28.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 47%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (1 analysts) rates it none, with a mean price target of $60.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 47%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (1 analysts) rates it none, with a mean price target of $60.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 47%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (1 analysts) rates it none, with a mean price target of $60.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $15.00 | -11.8% | · | $882 | -11.8% |
| 2 months | $12.53 | +5.6% | · | $1,056 | +5.6% |
| 3 months | $14.05 | -5.8% | · | $942 | -5.8% |
| 6 months | $29.70 | -55.4% | · | $446 | -55.4% |
| 1 year | $25.09 | -47.3% | · | $528 | -47.3% |
| 2 years | $9.30 | +42.3% | · | $1,423 | +42.3% |
| 3 years | $38.50 | -65.6% | · | $344 | -65.6% |
| 5 years | $248.75 | -94.7% | · | $53 | -94.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ARQQ does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.